Clinical Trials Directory

Trials / Completed

CompletedNCT03405402

Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
173 (actual)
Sponsor
Hanane EL KENZ · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Sickle cell patients have a high prevalence of alloimmunization. This high rate of alloimmunization can be partially explained by the existence of an antigenic difference between the predominantly Caucasian donor population and the sickle cell patients of African origin. Genetic and environmental risk factors have also been described. The main risk factors that have been shown in retrospective or cross-sectional studies are some HLA alleles, the age of the patient, the number of leukocyte-depleted erythrocyte concentrates (CED) transfused, the number of transfusion episodes, the age of the CEDs, the existence of an inflammatory event at the time of transfusion and the presence of anti-erythrocyte autoantibodies.There is also evidence of an impaired TH response but the underlying immunological mechanism is not fully understood. The aim of this study is to study the prevalence and the risk factors for anti-erythrocyte alloimmunization and to try to understand the immunological mechanisms.

Conditions

Interventions

TypeNameDescription
PROCEDUREBlood samplingExtra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis

Timeline

Start date
2018-02-13
Primary completion
2020-08-03
Completion
2020-08-03
First posted
2018-01-23
Last updated
2021-01-28

Locations

2 sites across 1 country: Belgium

Source: ClinicalTrials.gov record NCT03405402. Inclusion in this directory is not an endorsement.